CTA-specific Tetramers

Cancer testis antigens (CTA) constitutes a large group of tumor‐associated antigens with expression restricted to male germ cells in the testis. CTAs are not expressed in adult somatic tissues or during immunological development. In cancer, this gene control is lost, resulting in CTA expression in various types of tumors.

 

This tumor‐restricted pattern of expression, together with their robust in vivo immunogenicity, has identified CTAs as ideal targets for immunotherapeutic approaches, and encouraged the development of CTA‐based anti-cancer vaccines.

 

Important CT antigens in cancer therapy include MAGE-A1, MAGE-A3, MAGE-A4, NY-ESO-1, PRAME, CT83 and SSX2.

 

The Ludwig Institute for Cancer Research (LICR) maintains a database for cancer testis antigens.

 

The expression of cancer testis antigens in malignancies is heterogeneous and often relates to tumor progression. CTAs have been identified in melanoma, liver cancer, lung cancer, bladder cancer, and pediatric cancers such as neuroblastoma.

 

CTA-specific cytotoxic T-cell responses have been reported in patients with a variety of the above mentioned tumors. These responses can be determined by Tetramer assays for CD8+ CTA-specific T cells in peripheral blood and in tumor-infiltrating lymphocytes (TILs) from tumor biopsies.

 

Tetramer reagents from Tetramer Shop include Tetramers for detection of T cells specific for antigens derived from MAGE-A1, MAGE-A3 MAGE-A4, NY-ESO-1 and PRAME presented in context of MHC molecules HLA-A02:01, HLA-A24:02 and HLA-B07:02.

 

CTA relevant Tetramers >> Go to shop

 

Cat. No. HLA type Pep. Seq. Antigen
HA02-002 HLA-A*02:01 SLLMWITQV NY-ESO-1 157-165
HA02-003 HLA-A*02:01 SLLMWITQC NY-ESO-1 157-165 (9C)
HA02-007 HLA-A*02:01 KVLEYVIKV MAGEA1 278-286
HA02-004 HLA-A*02:01 KVAELVHFL MAGEA3 112-120
HA02-068 HLA-A*02:01 GVYDGREHTV MAGE-A4 230-239
HA02-138 HLA-A*02:01 VLDGLDVLL PRAME 100-108

Controls

 

Cat. No. HLA type Pep. Seq. Antigen
HA02-024 HLA-A*02:01 AVIAPVHAV None natural found
HA02-025 HLA-A*02:01 GVAGDVSAV None natural found
HA02-014 HLA-A*02:01 SLYNTVATL HIV-1 gag p17 76-84

 

Other relevant cancer related Tetramers >> Go to shop

 

Cat. No. HLA type Pep. Seq. Antigen
HA02-005 HLA-A*02:01 YMDGTMSQV Tyrosinase 369-377 (371D)
HA02-006 HLA-A*02:01 IMDQVPFSV gp100 (pmel17) 209-217
HA02-019 HLA-A*02:01 ITDQVPFSV gp100 (pmel) 209-217
HA02-001 HLA-A*02:01 ELAGIGILTV MelanA / MART 26-35
HA24-001 HLA-A*24:02 AFLPWHRLF Tyrosinase 188-196
HA24-022 HLA-A*24:02 VYFFLPDHL gp100-intron 4 (170-178)
HB07-006 HLA-B*07:02 LPWHRLFLL Tyrosinase 208-216

 

Application of CTA-specific Tetramers

Tetramers are useful in Tetramer protocols for detection, enumeration and isolation of antigen-specific CD8+ T cells in a variety of applications e.g. during cancer vaccine – and immunotherapeutic development. CTA-specific Tetramers can be used for profiling of CTA-specific T-cell responses to vaccines by monitoring of pre-existing and induced immunity.

 

General information about MHC Tetramers from Tetramer Shop

Tetramer Shop supply MHC Tetramers in various test sizes and the colors PE, BV421, BUV395, APC-Cy™7, APC, BV510, BV480, PE-Cy™5, PE-CF594, PE-Cy™7, PerCP-Cy™5.5, PerCP, FITC, BV605 and BUV737. For other colors, please enquire.

 

Tetramer Shop also supply Empty Loadable Tetramers for instant loading of peptide antigens essentially representing DIY Tetramers.